Taisei Corporation (TYO:1801)

CTI BioPharma Revenue

Taisei had revenue of 440.34B JPY in the quarter ending June 30, 2025, a decrease of -3.66%. This brings the company's revenue in the last twelve months to 2.14T, up 12.91% year-over-year. In the fiscal year ending March 31, 2025, Taisei had annual revenue of 2.15T with 22.05% growth.

• Revenue (ttm): 2,137.50B
• Revenue Growth: +12.91%
• P/S Ratio: 0.75
• Revenue / Employee: 130.48M
• Employees: 16,382
• Market Cap: 1,593.37B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	2,154.22B	389.20B	22.05%
Mar 31, 2024	1,765.02B	122.31B	7.45%
Mar 31, 2023	1,642.71B	99.47B	6.45%
Mar 31, 2022	1,543.24B	63.10B	4.26%
Mar 31, 2021	1,480.14B	-271.19B	-15.48%